

How can we improve outcomes for our patients with major depressive disorder?

Industry Satellite Symposium and Industry Mini Session on the occasion of the 35th ECNP Congress Hybrid, with financial support provided by H. Lundbeck A/S

Join us at ECNP for a satellite symposium and mini session



Industry Satellite Symposium

Optimising outcomes in major depressive disorder (MDD): managing patients who are not fully responsive to initial antidepressant treatment

Saturday 15 October 2022, 13:30–15:00
Hall F2, Austria Center Vienna

Speakers: George Papakostas (Chair), Roger McIntyre and Susana Sousa Almeida

Industry Mini Session

Functioning as a treatment goal in major depressive disorder (MDD): how can we improve patient outcomes?

Saturday 15 October 2022, 09:45–10:30
Hall E2, Austria Center Vienna

Speakers: Raymond Lam (Chair), Nina Schweinfurth-Keck and Andrea Fagiolini



The European Accreditation Committee in CNS (EAC/C) has granted 2 CME credits to the Industry Satellite Symposium and 1 CME credit to the Industry Mini Session. Both in-person and online participants can claim CME credits via the online congress platform.



Find the agendas for our exciting satellite symposium and mini session below, which will each be followed by Q&A sessions giving you the opportunity to send your questions to the speakers.

Industry Satellite Symposium, Saturday 15 October, 13:30–15:00 Optimising outcomes in major depressive disorder (MDD): managing patients who are not fully responsive to initial antidepressant treatment



How should we define and assess partial response to antidepressant treatment?

George Papakostas (USA)



Antidepressant use in patients with a partial response to treatment: what is the latest evidence?

Roger McIntyre (Canada)



Optimising treatment outcomes in partial responders: when to increase dose, augment or switch?

Susana Sousa Almeida (Portugal)

Industry Mini Session, Saturday 15 October, 09:45–10:30 Functioning as a treatment goal in major depressive disorder (MDD): how can we improve patient outcomes?

Welcome and introduction
Raymond Lam (Canada), Chair



How does co-morbidity with generalised anxiety disorder (GAD) impact on the functioning of patients with major depressive disorder (MDD)?
Nina Schweinfurth-Keck (Switzerland)



Antidepressant treatment in major depressive disorder (MDD): a focus on improvement in functioning in patients with co-morbid generalised anxiety disorder (GAD)
Andrea Fagiolini (Italy)

